Stem cell therapy
Frontier · Evidence and recent research
Notify me when meaningful evidence changes.
Where things stand
Cell therapies have legitimate, specific medical applications, but that does not validate broadly marketed anti-ageing infusions. The FDA warns that unapproved regenerative products can cause serious harm. Each product and indication needs its own clinical evidence; calling something a stem-cell treatment is not evidence of rejuvenation, effectiveness or safety. Source ↗ Recently: No update dated within the past 30 days is recorded in our collection. This describes our coverage, not a conclusion that the wider research is unchanged.
AI-written overview · not expert-reviewed · Background sources checked Sep 23, 2026 · Recent updates cover the last 30 days of this collection. A new report does not automatically change the evidence assessment.
What the research suggests
AI-reviewed · not yet expert-reviewedUpdated Sep 26, 2026 · 1 selected abstract · checked by a second AI pass
The short version
No conclusions about stem cell therapy in people, or about lifespan or health outcomes, can be drawn from these abstracts. The reported findings describe a molecular mechanism affecting cell ageing markers in cultured cells.[1]
What it is
In these abstracts, the only supplied study is a laboratory one on bone marrow mesenchymal stem cells (a cell type used in transplantation) exposed to hydrogen peroxide to imitate oxidative stress, plus a rat model of bone loss. It examines molecules (USP22, SPI1, NAMPT) linked to cell ageing in the dish, not a stem cell treatment given to people.[1]
Human evidence
No human finding could be established from the abstracts included in this review.
Animal & laboratory evidence
In these abstracts, SPI1 protein levels were reported to be lower both in hydrogen-peroxide-treated cells and in rats whose ovaries were removed to model bone thinning; increasing SPI1 in cells reduced ageing markers and restored bone-forming capacity in the dish. This is mechanistic, not a treatment result.[1]
Raising USP22 (an enzyme that removes tags marking proteins for destruction) reduced signs of cell ageing in these cultured cells, and the effect disappeared when SPI1 was lowered — consistent with the proposed pathway, but measured only with laboratory markers.[1]
How strong is this evidence?
Qualitatively very weak as evidence for any human use: a single mechanistic study in cultured cells with an animal model, using artificially applied hydrogen peroxide and staining-based ageing markers, with no people and no clinical endpoints reported.[1]
Risks & safety
The included abstracts do not provide enough information for a safety assessment. Missing reporting does not establish safety.
What remains uncertain
The abstract states the underlying mechanisms are poorly understood, and reports no safety, dosing or outcome data in people; missing reporting must not be read as evidence of safety or benefit.[1]
Whether these laboratory changes would improve the success of stem cell transplantation is untested here; the abstract only notes that senescence often compromises such therapy.[1]
Sources & review scope
This is an AI first pass over 1 selected abstract from 1 eligible collected publications, not a systematic review or full-text assessment. Selection combines recent papers with reviews and trials. Related or overlapping publications are not independent confirmations. This review does not assign a clinical recommendation or numeric score. Newer research may not yet be included.
- [1] USP22 alleviates oxidative stress-induced BMSCs senescence by stabilizing SPI1 protein. ↗Molecular genetics and genomics : MGG · 2026
Updated after the collected source material changed.
Background and coverage
FDA: unapproved regenerative therapies ↗
- Regulatory status
- Investigational
- Availability
- Limited
- Category
- Frontier
- Human results verified here
- 1
Evidence collection is needs review. 0 approved assessments; 55 assessments awaiting review; 3 published studies with verified results. Safety: not assessed.
Recorded evidence activity (experimental)
A numeric breakdown will be available after baseline review. Safety is not yet assessed.
What changed
Evidence events affecting this intervention
Curcumin reduced oxidative stress and promoted neural differentiation in cultured stem cells in vitro.
This in vitro study tested curcumin's effects on C17.2 neural stem cells exposed to oxidative stress. Curcumin-treated cells showed improved survival, reduced reactive oxygen species levels, enhanced antioxidant markers, and promoted differentiation into neurons and astrocytes, with apparent involvement of the Wnt3α/β-catenin/Cyclin D1 signaling pathway.
Systematic review examines molecular mechanisms of skin aging and therapeutic approaches including stem cell therapy.
This is a narrative review that describes the phenotypes and mechanisms of skin aging, including reduced regenerative capacity, chronic inflammation, impaired barrier function, oxidative stress, DNA damage, and epigenetic alterations. The authors evaluate recent research on pharmacological interventions and stem cell therapy for mitigating skin aging, along with delivery systems for natural compounds and the potential of AI in drug discovery. No specific efficacy data or effect sizes for stem cell therapy are reported.
Systematic review finds extracellular vesicles may modulate inflammation and support cartilage repair in osteoarthritis.
This systematic review examined how extracellular vesicles (EVs)—small membrane-enclosed particles carrying cellular cargo—influence osteoarthritis pathology and potential treatment. The authors describe a "pathological EV cycle" in which EVs from inflammatory cells drive cartilage degradation and bone remodeling, while EVs from therapeutic cells like mesenchymal stromal cells may suppress inflammation and promote tissue repair. The review identifies engineering improvements in EV delivery and potency but notes significant limitations in translating this approach to clinical use.
USP22 protein reduces senescence in bone marrow stem cells exposed to oxidative stress in vitro
This in vitro study examined how USP22 affects bone marrow mesenchymal stem cells (BMSCs) exposed to hydrogen peroxide to simulate oxidative stress. Researchers found that USP22 stabilized the SPI1 protein through deubiquitination, which increased NAMPT expression and NAD+ levels, reducing cellular senescence markers and preserving the cells' capacity to differentiate into bone tissue.
Phase IIa trial evaluates safety and feasibility of subretinal OpRegen stem cell delivery in geographic atrophy.
This Phase IIa open-label single-arm study assessed the surgical feasibility and safety of subretinal delivery of OpRegen (a stem cell therapy) in patients with geographic atrophy secondary to age-related macular degeneration. The trial also evaluated preliminary activity of the intervention. A substudy explored incorporation of advanced retinal imaging as an assessment tool.
Senolytic and anti-fibrotic agents tested to enhance stem cell therapy for knee osteoarthritis in RCT
This prospective, randomized, double-blind, active-control trial evaluated whether a senolytic agent (Fisetin) and an anti-fibrotic agent (Losartan), used independently and in combination, could improve the effect of autologous bone marrow aspirate concentrate (BMAC) injection into osteoarthritic knees. The abstract provided reports the trial design and intervention structure but does not report results, efficacy outcomes, or safety findings.
Proposed RCT of fisetin on stem cell function and kidney outcomes in advanced chronic kidney disease
This is a proposed study protocol, not a completed trial. The researchers planned to examine whether fisetin would improve adipose tissue-derived mesenchymal stem/stromal cell function, kidney function, inflammation markers, and physical function in individuals with advanced chronic kidney disease. No results are reported because the study has not been conducted.
Mesenchymal stem cell therapy associated with mobility improvements in frailty; systematic review of three small trials
This systematic review identified three randomized controlled trials (total ~208 older adults with aging frailty) examining intravenous mesenchymal stem cell therapy. MSC administration was well-tolerated with no serious adverse events reported. Studies showed variable improvements in functional measures: one trial reported dose-dependent increases in 6-minute walk distance at nine months; others reported improvements in SPPB, Timed Up and Go, and grip strength. Quality of life improved and pro-inflammatory cytokine concentrations decreased, though effect sizes and confidence intervals were not consistently provided.
Assessment history
The 25 most recent recorded changes, including corrections and backfill